On additional information regarding the delisting risk of ordinary shares of Cara Therapeutics, Inc. (CARA)

The International Trading System Limited (hereinafter – ITS) hereby informs on the delisting risk of ordinary shares of Cara Therapeutics, Inc. (ISIN US1407551092, hereinafter – Shares, QI) from the Nasdaq Stock Market LLC (hereinafter - Nasdaq).

Information on the delisting risk of ordinary shares by Nasdaq

As previously disclosed, On February 2, 2024, Cara Therapeutics, Inc. (hereinafter - Company) submitted Current report on Form 8-K to The United States Securities and Exchange Commission (the “SEC”). According to the report, on February 1, 2024 the Company received a notice from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock had been below $1.00 per share for the last 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days, or until July 30, 2024 to regain compliance with the Minimum Bid Price Requirement.

On August 1, 2024, the Company submitted Current report on Form 8-K to The United States Securities and Exchange Commission (the “SEC”). According to the report, on July 31, 2024, Nasdaq notified the Company that it was granted an extension of 180 days, or until January 27, 2025, to regain compliance with the requirement to maintain a minimum closing bid price of $1.00 per share.

If the Company fails to regain compliance prior to the expiration of the extension period, Nasdaq will provide written notification that the Company’s securities will be delisted. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS Ltd.

ITS conducts regular monitoring of the relevant information disclosed by the Company. Delisting of the Shares by Nasdaq will be considered to constitute a breach of the ITS Regulations on admitting financial instruments to trading and result in termination of trading in the QI on ITS.